Abstract
TO produce a vaccine against cancer, antigens must be found that are preferentially expressed by tumour cells and can induce an immune response against the tumour. The variable regions of the immunoglobulin molecules expressed on malignant B cells (idiotypes) are tumour-specific, but are weak immunogens. To induce an immune response in animals or humans, the idiotypic protein has therefore to be chemically coupled to a strongly immunogenic protein and mixed with an adjuvant1–8. The resulting response can protect animals from subsequent tumour challenge, and cure animals with established tumours in combination with chemo-therapy. Granulocyte-macrophage colony-stimulating factor (GM-CSF) augments antigen presentation in a variety of cells9–12. Here we show that by fusing a tumour-derived idiotype to GM-CSF, it can be converted into a strong immunogen capable of inducing idiotype-specific antibodies without other carrier proteins or adjuvants and of protecting recipient animals from challenge with an otherwise lethal dose of tumour cells. This approach may be applicable to the design of vaccines for a variety of other diseases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lynch, R. G., Graff, R. J., Sirisinha, S., Simms, E. S. & Eisen, H. N. Proc. natn. Acad. Sci. U.S.A. 69, 1540–1544 (1972).
Sugai, S., Palmer, D. W., Talal, N. & Witz, I. P. J. exp. Med. 140, 1547–1558 (1974).
Freedman, P. M., Autry, J. R., Tokuda, S. & Williams, R. J. J. natn. Cancer Inst. 56, 735–740 (1976).
Campbell, M. J. et al. J. Immun. 139, 2825–2833 (1987).
Kaminski, M. S., Kitamura, K., Maloney, D. G. & Levy, R. J. Immun. 138, 1289–1296 (1987).
George, A. J., Folkard, S. G., Hamblin, T. J. & Stevenson, F. K. J. Immun. 141, 2168–2174 (1988).
Campbell, M. J., Esserman, L. & Levy, R. J. Immun. 141, 3227–3233 (1988).
Kwak, L. W. et al. New Engl. J Med. 327, 1209–1215 (1992).
Morrissey, P. J., Bressler, L., Park, L. S., Alpert, A. & Gillis, S. J. Immun. 139, 1113–1119 (1987)
Heufler, C., Koch, F. & Schuler, G. J. exp. Med. 167, 700–705 (1988).
Fischer, H. G., Frosch, S., Reske, K. & Reske, K. A., J. Immun. 141, 3882–3888 (1988).
Smith, P. D., Lamerson, C. L., Wong, H. L., Wahl, L. M. & Wahl, S. M. J. Immun. 144, 3829–3834 (1990).
Bergman, Y. & Haimovich, J. Eur. J. Immun. 7, 413–417 (1977).
Maloney, D. G., Kaminski, M. D., Burowski, D., Haimovich, J. & Levy, R. Hybridoma 4, 191–209 (1985).
Holmes, K. L., Palaszynski, E., Frednckson, T. N., Morse, H. C. & Ihle, J. N. Proc. natn. Acad. U.S.A. 82, 6687–6691 (1985).
Ullrich, A. & Schlessinger, J. Cell 61, 203–212 (1990)
Curtis B. M. et al. Proc. natn. Acad. Sci. U.S.A. 88, 5809–5813 (1991)
Nicola, N. A. & Metcalf, D. Cell 67, 1–4 (1991).
Lopez, A. F., Elliott, M. J., Woodcock, J. & Vadas, M. A. Immun. Today 13, 495–500 (1992).
Lusis, A. J., Quon, D. H. & Golde, D. W. Blood 57, 13–21 (1981).
Carroll, W. L. Starnes, C. O., Levy, R. & Levy, S. J. exp. Med. 168, 1607–20 (1988).
Starnes, C. O. et al. J. Immun. 141, 333–339 (1988).
Tepper, R. I., Pattengale, P. K. & Leder, P. Cell 57, 503–512 (1989).
Fearon, E. R. et al. Cell 60, 397–403 (1990).
Gansbacher, B. et al. Cancer Res. 50, 7820–7825 (1990).
Blankenstein, T. et al. J. exp. Med. 173, 1047–1052 (1991).
Hock, H., Dorsch, M., Diamantstein, T. & Blankenstein, T. J. exp. Med. 174, 1291–1298 (1991).
Hinuma, S., Hazama, M., Mayumi, A. & Fujisawa, Y. FEBS Lett. 288, 138–142 (1991).
Allison, A. C. & Byars, N. E. J. immun. Meth. 95, 157–168 (1986).
Shin, S. U. & Morrison, S. L. Meth. Enzym. 178, 459–476 (1989).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tao, MH., Levy, R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362, 755–758 (1993). https://doi.org/10.1038/362755a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/362755a0
This article is cited by
-
Fusion cytokine IL-2-GMCSF enhances anticancer immune responses through promoting cell–cell interactions
Journal of Translational Medicine (2016)
-
Modulation of tumor immunity by therapeutic monoclonal antibodies
Cancer and Metastasis Reviews (2011)
-
Progress and challenges in the vaccine-based treatment of head and neck cancers
Journal of Experimental & Clinical Cancer Research (2009)
-
Strategies for enhancing DNA vaccine potency by targeting antigen-presenting cells
Frontiers of Agriculture in China (2009)
-
Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity
BMC Immunology (2008)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.